Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin in Asian adult patients with chronic HCV genotype 1b infection and compensated cirrhosis
Lai Wei,Guiqiang Wang,Kopecky-Bromberg Sarah,Jun Cheng,Qing Xie,Maorong Wang,Min Xu,Zhongping Duan,Jinlin Hou,Mingxiang Zhang,Yuexin Zhang,Hong Tang,Wei Zhao,Shumei Lin,Zhansheng Jia,Junqi Niu,Zhiliang Gao,Hong Yuan,Minghua Lin,Xinmin Zhou,Yan Luo,Fredrick Linda,Mobashery Niloufar,Ye Wang,Jidong Jia
DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2018.05.008
2018-01-01
Abstract:Objective To evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) 25/150/100 mg once daily and dasabuvir (DSV) 250 mg twice daily combined with ribavirin in adult patients of Mainland China with chronic HCV genotype 1b infection and compensated cirrhosis.Methods An open-label,multicenter,phase 3 clinical trial study was conducted in mainland China,Taiwan,and South Korea.Adult patients with compensated cirrhosis (Metavir score =F4) who were newly diagnosed and treated for hepatitis C virus genotype lb infection with ombitasvir/paritaprevir/ritonavir and dasabuvir combined with ribavirin for 12 weeks were included.Assessed SVR rate of patients obtained at 12 and 24 weeks after drug withdrawal.Efficacy and safety were evaluated in patients who received at least one time study drugs.Results A total of 63 patients from mainland China were enrolled,62 of whom (98.4％) had a baseline Child-Pugh score of 5 points.The overall rate of SVR12 and SVR24 in patients was 100％ (95％ CI:94.3％ to 100.0％).Most of the adverse events that occurred were mild.The incidence of common (≥ 10％) adverse events and laboratory abnormalities included elevated total bilirubin (36.5％),weakness (19.0％),elevated unconjugated bilirubin (19.0％) and conjugated bilirubin (17.5％),and anemia (14.3％).Three cases (4.8％) of patients experienced Grade ≥ 3 adverse events that were considered by the investigators to be unrelated to the study drug.None patients had adverse events leading to premature drug withdrawal.Conclusion Mainland Chinese patients with chronic HCV genotype lb infection and compensated cirrhosis who were treated with OBV/PTV/r plus DSV combined with RBV for 12 weeks achieved 100 ％ SVR at 12 and 24 weeks after drug withdrawal.Tolerability and safety were good,and majority of adverse events were mild.